CROSSJECT Aktie

2,02 EUR +0,02 EUR +1,10 %

28.11.2024

STU

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.84,76 Mio. EUR

Div. Rendite0,00%

WKNA1XEH4

ISINFR0011716265

SymbolCRJTF

CROSSJECT Aktien News

Sortieren:Datum Meistgelesen

13.11.24GlobeNewswireCrossject’s ZENEO® Auto-Injector's usability further demonstrated in extreme HAZMAT conditions

22.10.24GlobeNewswireCrossject reports strong manufacturing progress with its epilepsy rescue therapy ZEPIZURE® ahead of filing U.S. Emergency Use Authorization

26.09.24GlobeNewswireCrossject announces its eligibility for France’s PEA-PME investment scheme

WerbungCROSSJECT-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

23.09.24GlobeNewswireCrossject reports financial results and business highlights for the first six months of 2024

17.09.24GlobeNewswireCrossject to report first-half 2024 financial results and host webcast on September 23, 2024

22.08.24GlobeNewswireCrossject to Present at the H.C. Wainwright 26th Annual Global Investment Conference, September 9th-11th, 2024

19.08.24GlobeNewswireCrossject appoints Tony Tipton as U.S. Chief Operating Officer in Preparation for Commercialization of ZEPIZURE® Epilepsy Rescue Treatment

18.07.24GlobeNewswireCrossject achieves key ZEPIZURE® manufacturing milestone

15.07.24GlobeNewswireCrossject to attend H.C. Wainwright 26th Annual Global Investment Conference

10.07.24GlobeNewswireCrossject is awarded a 6.9 million euros financing from the French Government, as part of the France 2030 innovation plan, to accelerate the development of ZENEO® Epinephrine

26.06.24GlobeNewswireCrossject elaborates on ZEPIZURE® potential in light of landmark RAMPART study and its own, recently published, bioequivalence study

12.06.24GlobeNewswireCrossject appoints Dan Chiche, MD as Chief Medical Officer North America

04.06.24GlobeNewswireCrossject announces highly successful closing of its €8 million rights offering

30.05.24GlobeNewswireCrossject announces publication of clinical data on ZEPIZURE ® in Neurology and Therapy

02.05.24GlobeNewswireCrossject signs a geographic extension of ZEPIZURE® commercialization agreement in Europe

25.04.24GlobeNewswireCrossject reports audited financial results for 2023

02.04.24GlobeNewswireCrossject trading on Euronext to resume as usual on Wednesday April 3

02.04.24GlobeNewswireCrossject advances in its U.S. Strategy and reports Financial Results for 2023

08.03.24GlobeNewswireCrossject gender equality score reaches 96/100 in 2024

27.02.24GlobeNewswireCrossject obtains a financing up to €12 million, in two tranches

06.02.24GlobeNewswireCrossject provides strategic update on priorities for 2024

01.02.24GlobeNewswireCrossject to host a business briefing on commercial strategy on February 6 at 17:30 CET

09.01.24GlobeNewswireCrossject to present at Biotech Showcase on January 9 at 16:30 PT

04.01.24GlobeNewswireCrossject engages Syneos Health for U.S. commercial launch of ZEPIZURE®

22.12.23GlobeNewswireCrossject signs ZEPIZURE® commercialization agreement for northern Europe

28.11.23GlobeNewswireCrossject announces initiation of coverage by ODDO BHF

26.09.23GlobeNewswireCrossject reports financial results and business highlights for first half of 2023

11.09.23GlobeNewswireCrossject announces significant improvement in Gaïa ESG rating

05.09.23GlobeNewswireCrossject reports successful completion of European and U.S. audits for manufacturing of ZENEO® Midazolam for epileptic seizures

20.07.23GlobeNewswireCrossject signs new licensing agreement on ZENEO® Midazolam epilepsy rescue therapy with AFT Pharmaceuticals for Australia & New Zealand

01.06.23GlobeNewswireCrossject - Appointment of Daniel Teper to the Crossject Supervisory Board / Building skills to support the US transition

21.03.23GlobeNewswireCrossject - 2022 Annual Results

20.03.23GlobeNewswireCROSSJECT - 2022 Annual Results

CROSSJECT News

CROSSJECT News: auf dieser Seite finden Sie alle CROSSJECT News und Nachrichten zur CROSSJECT Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch CROSSJECT News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um CROSSJECT News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.